Details of the Drug

General Information of Drug (ID: DM6AUHV)

Drug Name

Fostamatinib

Synonyms

901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN]

Indication

Disease Entry	ICD 11	Status	REF
Immune thrombocytopenic purpura	3B64.13	Approved	[1]
Rheumatoid arthritis	FA20	Phase 3	[2], [3]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

580.5

Topological Polar Surface Area (xlogp)

1.6

Rotatable Bond Count (rotbonds)

10

Hydrogen Bond Donor Count (hbonddonor)

4

Hydrogen Bond Acceptor Count (hbondacc)

15

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.5 h [4]
Bioavailability: The bioavailability of drug is 55% [4]
Clearance: The apparent oral clearance of drug is 300 mL/min [4]
Elimination: About 80% of R406 is excreted in the feces, primarily as the O-glucuronide conjugate and the O-desmethyl metabolite produced by gut bacteria [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 406 hours [4]
Metabolism: The drug is metabolized via the alkaline phosphatase to the active metabolite R406 [6]
Vd: The volume of distribution (Vd) of drug is 400 L [4]

Chemical Identifiers

Formula: C23H26FN6O9P
IUPAC Name: [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate
Canonical SMILES: CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C
InChI: InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)
InChIKey: GKDRMWXFWHEQQT-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 11671467
CAS Number: 901119-35-5
DrugBank ID: DB12010
TTD ID: D0V8HJ
VARIDT ID: DR00300
INTEDE ID: DR0754
ACDINA ID: D01107

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase SYK (SYK)	TTOU65C	KSYK_HUMAN	Modulator	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
ATP-binding cassette sub-family B member 5 (ABCB5)	DTKVEXO	ABCB5_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[]
Alkaline phosphatase (ALPL)_{Main DME}	DEVEFKM	PPBT_HUMAN	Substrate	[]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Immune thrombocytopenic purpura

ICD Disease Classification

3B64.13

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tyrosine-protein kinase SYK (SYK)	DTT	SYK	3.05E-05	0.29	0.43
ATP-binding cassette sub-family B member 5 (ABCB5)	DTP	ABCB5	3.35E-01	-2.42E-02	-1.22E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.90E-01	2.35E-02	7.88E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fostamatinib

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Fostamatinib due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[29]
-----------

Coadministration of a Drug Treating the Disease Different from Fostamatinib (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Fostamatinib and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[30]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Fostamatinib caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[31]
Gilteritinib	DMWQ4MZ	Moderate	Decreased clearance of Fostamatinib due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[32]
Oliceridine	DM6MDCF	Moderate	Decreased metabolism of Fostamatinib caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[31]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Fostamatinib caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[31]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Fostamatinib and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[33]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Fostamatinib caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Ripretinib	DM958QB	Moderate	Decreased clearance of Fostamatinib due to the transporter inhibition by Ripretinib.	Gastrointestinal stromal tumour [2B5B]	[30]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Fostamatinib caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[31]
Ubrogepant	DM749I3	Moderate	Decreased clearance of Fostamatinib due to the transporter inhibition by Ubrogepant.	Migraine [8A80]	[34]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Fostamatinib caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[35]
Upadacitinib	DM32B5U	Moderate	Decreased metabolism of Fostamatinib caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[31]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Fostamatinib caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[31]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Fostamatinib caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[36]
Larotrectinib	DM26CQR	Moderate	Decreased clearance of Fostamatinib due to the transporter inhibition by Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[30]
Fluticasone	DMGCSVF	Moderate	Decreased metabolism of Fostamatinib caused by Fluticasone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[31]
Betrixaban	DM2C4RF	Moderate	Decreased clearance of Fostamatinib due to the transporter inhibition by Betrixaban.	Venous thromboembolism [BD72]	[31]
-----------


⏷ Show the Full List of 17 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Haematite red	E00236	14833	Colorant
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Fostamatinib 100 mg tablet	100 mg	Tablet	Oral
Fostamatinib 150 mg tablet	150 mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7796).
3	ClinicalTrials.gov (NCT01197521) Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.. U.S. National Institutes of Health.
4	Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. Br J Clin Pharmacol. 2013 Jul;76(1):78-88. doi: 10.1111/bcp.12048.
5	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6	Fohner AE, McDonagh EM, Clancy JP, Whirl Carrillo M, Altman RB, Klein TE: PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2017 Jan;27(1):39-42. doi: 10.1097/FPC.0000000000000246.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
8	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB12010)
9	Effects of CYP3A4 inhibitors ketoconazole and verapamil and the CYP3A4 inducer rifampicin on the pharmacokinetic parameters of fostamatinib: results from In vitro and phase I clinical studies. Drugs R D. 2016 Mar;16(1):81-92.
10	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19	ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005 May 15;65(10):4320-33.
20	NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
21	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
22	Company report (Portola Pharmaceuticals)
23	J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
24	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
25	An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
26	Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
27	Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243.
28	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
29	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
30	Cerner Multum, Inc. "Australian Product Information.".
31	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
32	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
33	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
34	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
35	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
36	Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.